Overview

Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if AR-67 is effective in the treatment for patients with MDS.
Phase:
Phase 2
Details
Lead Sponsor:
Arno Therapeutics
Treatments:
10-hydroxycamptothecin
Camptothecin